4-bromo-3,3-dimethyl-butyric acid | 854432-06-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 4-bromo-3,3-dimethyl-butyric acid
• 英文别名: 4-Brom-3,3-dimethyl-buttersaeure；4-Bromo-3,3-dimethylbutanoic acid
• CAS: 854432-06-7
• 化学式: C₆H₁₁BrO₂
• mdl: MFCD20625256
• 分子量: 195.056
• InChiKey: OGSIWPPNFLFXOH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-bromo-3,3-dimethyl-butyric acid 在 硫酸 、 silver fluoride 作用下， 生成 4-fluoro-3,3-dimethyl-butyric acid ethyl ester
  参考文献：
  名称：

  581.含有CF链接的有毒氟化合物。第七部分 体内ω-氟羧酸的β-氧化的证据。

  摘要：

  DOI：

  10.1039/jr9490002745
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 四氯化碳 、 溴 作用下， 生成 4-bromo-3,3-dimethyl-butyric acid
  参考文献：
  名称：

  22.溴对有机酸银盐的作用研究

  摘要：

  DOI：

  10.1039/jr9500000100

文献信息

• Substituted aryl or heteroarylpiperidine derivatives as melanocortin-4 receptor modulators
  申请人：Santhera Pharmaceuticals (Schweiz) AG

  公开号：EP2020405A1

  公开（公告）日：2009-02-04

  The present invention relates to substituted aryl or heteroarylpiperidine derivatives of structure (I) as melanocortin-4 receptor modulators. Depending on the structure and the stereochemistry the compounds of the invention are either selective agonists or selective antagonists of the human melanocortin-4 receptor (MC-4R). The agonists can be used for the treatment of disorders and diseases such as obesity, diabetes and sexual dysfunction, whereas the antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, anxiety and depression. Generally all diseases and disorders where the regulation of the MC-4R is involved can be treated with the compounds of the invention.

  本发明涉及结构式(I)的取代芳基或杂芳基哌啶衍生物，作为黑色素皮质素-4受体调节剂。根据结构和立体化学，本发明的化合物可以是人类黑色素皮质素-4受体(MC-4R)的选择性激动剂或选择性拮抗剂。激动剂可用于治疗肥胖、糖尿病和性功能障碍等疾病，而拮抗剂可用于治疗癌症恶病质、肌肉消耗、厌食症、焦虑和抑郁等疾病。一般来说，所有涉及MC-4R调节的疾病和疾病都可以用本发明的化合物进行治疗。
• [EN] COMPOUNDS FOR THE TREATMENT OF HIV<br/>[FR] COMPOSÉS POUR TRAITER LE VIH
  申请人：GILEAD SCIENCES INC

  公开号：WO2013006738A1

  公开（公告）日：2013-01-10

  The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.

  本发明提供了如下式（I）的化合物或其盐，还提供了包含如下式（I）化合物的药物组合物，制备如下式（I）化合物的方法，用于制备如下式（I）化合物的中间体以及治疗Retroviridae病毒感染的治疗方法，包括由HIV病毒引起的感染。
• Diaryl piperazineacetamides as antimuscarinic agents
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0585500A1

  公开（公告）日：1994-03-09

  Diaryl piperzineacetamide compounds useful as antimuscarinic agents for treating a variety of indications such as Parkinson's disease, motion sickness and for the inhibition of gastric acid secretion.

  Diaryl piperzineacetamide化合物可用作抗胆碱能药物，用于治疗多种疾病，如帕金森病、晕动病以及抑制胃酸分泌。
• Conjugates of the B-subunit of shiga toxin for use as contrasting agents for imaging and therapy
  申请人：Institut Curie

  公开号：EP2740491A1

  公开（公告）日：2014-06-11

  Multivalent conjugates comprising the following formula: (STxB-linker A-S)x-GNS-(S-linker B-T)y wherein STxB is the B-subunit of Shiga toxin; linker A is a noncleavable linker; linker B is a cleavable linker used to release at least one T or a noncleavable linker; GNS is a gold nanostructure; S is a sulfhydryl group and x and y can vary from 1 to 8,000; and T is a molecule selected from the group of: contrast agents, cytotoxic agents, prodrugs and antigens and x and y can vary from 1 to 10,000. These multivalent conjugates can be used in therapy to treat cancer and in medical imaging. Methods to distinguish normal cells from abnormal cells and methods for treating cancer by photothermal therapy or photothermal therapy and cytotoxic therapy are also part of the present invention.

  包含以下公式的多价结合物：(STxB-连接剂A-S)x-GNS-(S-连接剂B-T)y，其中STxB是Shiga毒素的B亚单位；连接剂A是不可切割的连接剂；连接剂B是可切割的连接剂，用于释放至少一个T或不可切割的连接剂；GNS是金纳米结构；S是硫醇基团，x和y可以在1到8000之间变化；T是从对比剂、细胞毒性剂、前药和抗原组中选择的分子，x和y可以在1到10000之间变化。这些多价结合物可用于治疗癌症和医学成像。区分正常细胞和异常细胞的方法以及通过光热疗法或光热疗法和细胞毒疗法治疗癌症的方法也是本发明的一部分。
• [EN] CONJUGATES OF THE B-SUBUNIT OF SHIGA TOXIN FOR USE AS CONTRASTING AGENTS FOR IMAGING AND THERAPY<br/>[FR] CONJUGUÉS DE LA SOUS-UNITÉ B DE TOXINE DE SHIGA DESTINÉS À ÊTRE UTILISÉS COMME AGENTS DE CONTRASTE EN IMAGERIE ET EN THÉRAPIE
  申请人：INST CURIE

  公开号：WO2014086942A1

  公开（公告）日：2014-06-12

  Multivalent conjugates comprising the following formula: (STxB-linker A-S)x-GNS-(S-linker B-T)y wherein STxB is the B-subunit of Shiga toxin; linker A is a noncleavable linker; linker B is a cleavable linker used to release at least one T or a noncleavable linker; GNS is a gold nanostructure; S is a sulfhydryl group and x and y can vary from 1 to 8,000; and T is a molecule selected from the group of: contrast agents, cytotoxic agents, prodrugs and antigens and x and y can vary from 1 to 10,000. These multivalent conjugates can be used in therapy to treat cancer and in medical imaging. Methods to distinguish normal cells from abnormal cells and methods for treating cancer by photothermal therapy or photothermal therapy and cytotoxic therapy are also part of the present invention.

  包含以下公式的多价结合物：(STxB-连接剂A-S)x-GNS-(S-连接剂B-T)y，其中STxB是志贺毒素的B亚单位；连接剂A是不可切割的连接剂；连接剂B是可切割的连接剂，用于释放至少一个T或不可切割的连接剂；GNS是金纳米结构；S是硫醇基团，x和y的值可在1到8,000之间变化；T是从对比剂、细胞毒剂、前药和抗原组中选择的分子，x和y的值可在1到10,000之间变化。这些多价结合物可用于治疗癌症和医学成像。区分正常细胞和异常细胞的方法以及通过光热疗法或光热疗法和细胞毒疗法治疗癌症的方法也属于本发明的一部分。